AnaptysBio’s trial saw 69% of its rheumatoid arthritis patients treated with rosnilimab achieve low disease activity by week ...

Rheumatoid arthritis is a heterogeneous and progressive autoimmune disease, and patients with this condition show varied responses to treatment. Practical, reliable, individually tailored measures ...

The vagus nerve, a complex bundle of 200,000 fibers connecting the brain to vital organs, has remained a medical enigma for ...

SAN DIEGO - AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company currently trading near its 52-week low at $12.38, announced significant findings from their Phase 2b RENOIR trial for ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

Patients with late-onset rheumatoid arthritis experienced greater functional impairment over 5 years, compared against those with younger-onset disease.

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.

AnaptysBio shares surged 37% in premarket trading Wednesday after a mid-stage trial evaluating a rheumatoid arthritis treatment achieved its primary endpoint. Shares were recently trading around $17.

Shares of AnaptysBio (NASDAQ:ANAB) climbed ~12% in the premarket on Wednesday after the biotech said its lead asset, rosnilimab, reached the main goals in a mid-stage trial targeted at the autoimmune ...

Higher low-carbohydrate diet (LCD) scores, characterized by reduced carbohydrate intake and increased protein consumption, are associated with a lower likelihood of rheumatoid arthritis (RA) among ...

DelveInsight’s, “HDAC Inhibitor Pipeline Insight” report provides comprehensive insights about 40+ companies and 50+ pipeline ...